Figure INF-6:  Estimated HCV antibody prevalence among injecting drug users – studies with national and sub-national coverage – Part (i) All injecting drug users, 2003 to 2004

Figure INF-06 part i

Notes:

Black square = samples with national coverage; blue triangle = samples with subnational (including local or regional) coverage.

Differences between countries have to be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary.

Data for Portugal, Slovenia and Slovakia are limited to prevalence among IDUs in treatment and may not be representative of prevalence among IDUs who are not in treatment.

Data for Spain and Portugal and part of the data for Czech Republic include non-IDUs and therefore may underestimate prevalence among IDUs (proportion of non-IDUs in the samples not known).

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

Reitox national focal points. For primary sources, study details and data before 2003, see Table INF-11.